Protalix Biotherapeutics Is A Biopharmaceutical Company Focused On Developingproducingand Commercializing Innovative Medicinesparticularly Recombinant Therapeutic Proteinsfounded In 1993 And Headquartered In Karmielisraelwith Operations In New Jerseyusaprotalix Is Publicly Traded On The American Stock Exchange And The Tel Aviv Stock Exchange Under The Ticker Plx The Company Utilizes Its Proprietary Procellex Plant Cell Based Protein Expression System To Create Therapeutic Proteins For Clinical Testingprotalix S Notable Products Include Elelysoan Enzyme Replacement Therapy For Type 1 Gaucher Diseaseand Elfabriowhich Received Fda And European Medicines Agency Approval In May 2023Protalix Has Partnered With Pfizer Incfor The Global Development Of Elelyso And With Chiesi Farmaceutici S P Afor Elfabrioshowcasing Its Commitment To Collaboration With Leading Pharmaceutical Companies To Expand The Reach Of Its Innovative Therapies
No conferences found for this company.
| Company Name | Protalix Biotherapeutics |
| Country |
Israel
|
| Address | N/A |
| Telephone | N/A |
| N/A |
